Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%

Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results

May 2, 2016 7:30 AM EDT

-- Total Net Revenues Up 12 Percent Year-Over-Year ---- EXPAREL® Net Revenues Up 14 Percent Year-Over-Year ---- Conference Call Today at 9 a.m. ET --

PARSIPPANY, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for... More